| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | fMet-Leu-Phe receptor, fMLP receptor, N-formyl peptide receptor, FPR, N-formylpeptide chemoattractant receptor, FPR1 |
| Entrez GeneID | 2357 |
| WB Predicted band size | 38.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This FPR1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 165-193 amino acids from the Central region of human FPR1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于FPR1抗体的3篇代表性文献的简要总结：
1. **文献名称**：*Targeting FPR1 for cancer therapy: inhibition of tumor cell migration and metastasis*
**作者**：Li, H. et al.
**摘要**：研究验证了FPR1抗体在体外和体内抑制肿瘤细胞迁移和转移的作用，发现其通过阻断FPR1介导的G蛋白信号通路，降低肿瘤侵袭性，为癌症治疗提供新策略。
2. **文献名称**：*Formyl peptide receptor 1 as a novel biomarker in chronic inflammation*
**作者**：Chen, Y., & Smith, J.
**摘要**：该文献报道了一种高特异性FPR1抗体在炎症性疾病诊断中的应用，证明FPR1在类风湿性关节炎和炎症性肠病组织中显著高表达，提示其可作为炎症活动度的生物标志物。
3. **文献名称**：*Structural basis of FPR1 activation by pathogenic peptides and antibody targeting*
**作者**：Wang, Q. et al.
**摘要**：通过冷冻电镜解析FPR1与其抗体的复合物结构，揭示了抗体通过结合受体胞外域变构抑制病原体衍生肽激活的分子机制，为设计靶向FPR1的抗体药物提供结构基础。
(注：以上为示例性内容，实际文献需通过PubMed/Google Scholar检索关键词"FPR1 antibody"获取。建议优先选择近5年发表在*Nature Immunology*、*Cell Reports*等期刊的研究。)
The formyl peptide receptor 1 (FPR1) is a G protein-coupled receptor (GPCR) predominantly expressed on immune cells, including neutrophils, monocytes, and macrophages. It plays a key role in detecting pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), particularly formylated peptides derived from bacterial proteins or mitochondrial debris during cellular stress. FPR1 activation triggers chemotaxis, phagocytosis, and inflammatory mediator release, bridging innate immunity and inflammatory responses. Dysregulation of FPR1 is linked to chronic inflammation, autoimmune disorders, and cancer progression, where it may either promote tumor growth or enhance anti-tumor immunity depending on context.
FPR1 antibodies are vital tools for studying receptor expression, localization, and function. They enable detection of FPR1 in tissues or cells via techniques like Western blotting, flow cytometry, and immunohistochemistry. Monoclonal antibodies offer high specificity for targeted epitopes, while polyclonal antibodies can detect multiple receptor conformations. These reagents are critical for exploring FPR1's role in disease models, including sepsis, rheumatoid arthritis, and metastatic cancers. Some studies highlight FPR1's potential as a therapeutic target, with antibodies being developed to modulate receptor activity—either blocking pathogenic signaling or enhancing immune responses.
Despite their utility, FPR1 antibodies require rigorous validation due to homology with other FPR family members (e.g., FPR2/3) and splice variants. Advances in antibody engineering aim to improve specificity and therapeutic applicability, particularly in targeting FPR1-mediated pathways in inflammatory diseases and oncology. Ongoing research continues to unravel its dual roles in immunity and pathology, driving demand for reliable antibody tools.
×
